Information Provided By:
Fly News Breaks for June 11, 2019
AERI
Jun 11, 2019 | 07:38 EDT
Canaccord analyst Dewey Steadman said Aerie Pharmaceuticals' Rhopressa and Rocklatan prescriptions were likely impacted by the Memorial Day holiday. As a result, the analyst does not believe the prescription run rate can meet his/consensus revenue expectations for the quarter and that estimates will likely need to come down ahead of its Q2 results. Steadman maintained his Buy rating and $56 price target on Aerie Pharmaceuticals shares.
News For AERI From the Last 2 Days
There are no results for your query AERI